<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04696757</url>
  </required_header>
  <id_info>
    <org_study_id>NORMANDY</org_study_id>
    <nct_id>NCT04696757</nct_id>
  </id_info>
  <brief_title>Non-OpeRative MANagement of Rectal Cancer Patients</brief_title>
  <acronym>NORMANDY</acronym>
  <official_title>Non-OpeRative MANagement of Rectal Cancer Patients Who Had Clinical Complete Response After Pre-operative Chemo-raDiotherapY</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kangbuk Samsung Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kangbuk Samsung Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a single-center, open, prospective, single-treatment trial (pilot study). This&#xD;
      study aims to analyze the treatment results after receiving capecitabine adjuvant&#xD;
      chemotherapy for 4 months after non-surgical treatment in patients who had completed and&#xD;
      could have clinical complete remission with capecitabine preoperative chemoradiotherapy with&#xD;
      capecitabine for mid-to-lower rectal cancer and to investigate the feasibility of&#xD;
      non-surgical treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Indication:&#xD;
&#xD;
        1. mid-to-lower rectal cancer was diagnosed histologically as adenocarcinoma in&#xD;
           preoperative examination,&#xD;
&#xD;
        2. the tumor was located at the lower boundary of the tumor spans the anorectal junction,&#xD;
           and the clinical stage is stage 2 or 3, and&#xD;
&#xD;
        3. clinical complete remission was confirmed after the treatment response evaluation at 8&#xD;
           weeks after completion of preoperative chemoradiotherapy according to MR/SFS and biopsy.&#xD;
&#xD;
      Aim:&#xD;
&#xD;
        1. to analyze the treatment results after receiving capecitabine adjuvant chemotherapy for&#xD;
           4 months after non-surgical treatment in patients who had completed and could have&#xD;
           clinical complete remission with capecitabine preoperative chemoradiotherapy with&#xD;
           capecitabine for mid-to-lower rectal cancer&#xD;
&#xD;
        2. to investigate the feasibility of non-surgical treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2018</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Aim: 1) to analyze the treatment results after receiving capecitabine adjuvant chemotherapy for 4 months after non-surgical treatment in patients who had completed and could have clinical complete remission with capecitabine preoperative chemoradiotherapy with capecitabine for mid-to-lower rectal cancer 2) to investigate the feasibility of non-surgical treatment.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>DFS</measure>
    <time_frame>Duration from Pre-operative CRT</time_frame>
    <description>Disease-free survival</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Rectal Cancer</condition>
  <condition>Chemoradiotherapy</condition>
  <condition>Watch &amp; Wait</condition>
  <arm_group>
    <arm_group_label>Cape</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Capecitabine without surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Capecitabine without surgery</description>
    <arm_group_label>Cape</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical CR after pre-operative CRT for Rectal cancer&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dong-Hoe Koo</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dong-Hoe Koo</last_name>
    <phone>+82-2001-8330</phone>
    <email>dhkoo.smc@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kangbuk Samsung Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-746</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dong-Hoe Koo, MD,PhD</last_name>
      <phone>+82-2-2001-8330</phone>
      <email>d.h.koo@samsung.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 4, 2021</study_first_submitted>
  <study_first_submitted_qc>January 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 6, 2021</study_first_posted>
  <last_update_submitted>January 4, 2021</last_update_submitted>
  <last_update_submitted_qc>January 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kangbuk Samsung Hospital</investigator_affiliation>
    <investigator_full_name>Dong-Hoe Koo</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Rectal Cancer</keyword>
  <keyword>Chemoradiotherapy</keyword>
  <keyword>Watch &amp; wait</keyword>
  <keyword>Capecitabine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

